Copyright
©The Author(s) 2017.
World J Gastroenterol. Nov 7, 2017; 23(41): 7459-7469
Published online Nov 7, 2017. doi: 10.3748/wjg.v23.i41.7459
Published online Nov 7, 2017. doi: 10.3748/wjg.v23.i41.7459
Costs - average, € (SD) | TDF | LAM+ADV | Difference TDF vs LAM+ADV | P value |
(n = 22) | (n = 24) | |||
Studied medication | 2966 (69) | 4218 (558) | -1252 | < 0.0011 |
Concomitant medication | 218 (599) | 82 (213) | 136 | 0.484 |
Medical visits | 505 (158) | 500 (137) | 5 | 0.942 |
Tests | 1388 (182) | 1363 (242) | 25 | 0.834 |
Admissions and surgeries | 0 (0) | 0 (0) | 0 (0) | NA |
Total | 4943 (1059) | 5811 (1538) | -868 | < 0.0011 |
- Citation: Rodríguez M, Pascasio JM, Fraga E, Fuentes J, Prieto M, Sánchez-Antolín G, Calleja JL, Molina E, García-Buey ML, Blanco MÁ, Salmerón J, Bonet ML, Pons JA, González JM, Casado MÁ, Jorquera F, the TENOSIMP-B Research Group. Tenofovir vs lamivudine plus adefovir in chronic hepatitis B: TENOSIMP-B study. World J Gastroenterol 2017; 23(41): 7459-7469
- URL: https://www.wjgnet.com/1007-9327/full/v23/i41/7459.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i41.7459